Islatravir: all 27 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kgNot yet recruitingNCT07862569Phase 2
• A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)RecruitingNCT07266831Phase 2/3
• A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)Active, not recruitingNCT05631093Phase 3Results posted
• A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)Active, not recruitingNCT05630755Phase 3Results posted
• Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVActive, not recruitingNCT05052996Phase 2Results posted
• Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)TerminatedNCT04652700Phase 3Results posted
• Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)TerminatedNCT04644029Phase 3Results posted
• Islatravir and Methadone Pharmacokinetics (MK-8591-029)CompletedNCT04568603Phase 1Results posted
• Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]CompletedNCT04564547Phase 2Results posted
• Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)CompletedNCT04515641Phase 1Results posted
• Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)CompletedNCT04303156Phase 1Results posted
• Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)CompletedNCT04295772Phase 2Results posted
• Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)CompletedNCT04233879Phase 3Results posted
• Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)CompletedNCT04233216Phase 3Results posted
• Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)CompletedNCT04223791Phase 3Results posted
• Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)CompletedNCT04003103Phase 2Results posted
• Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)CompletedNCT03272347Phase 2Results posted
• A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)CompletedNCT02217904Phase 1Results posted
• A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)CompletedNCT07086079Phase 1
• A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)Active, not recruitingNCT06891066Phase 2
• A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)CompletedNCT06811246Phase 1
• A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)CompletedNCT06719570Phase 1
• A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)CompletedNCT06619678Phase 1
• A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)Active, not recruitingNCT05766501Phase 3
• DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)Active, not recruitingNCT05705349Phase 3
• A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)WithdrawnNCT05130086Phase 2
• Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)WithdrawnNCT05115838Phase 2

← Islatravir overview